Hubei JXBio Pharmaceutical Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Hubei JXBio Pharmaceutical Co., Ltd.?

Yes. FDA’s import refusal records list 1 refused shipment line declared as made by Hubei JXBio Pharmaceutical Co., Ltd. (China) whose FDA product code names tirzepatide, on Aug 5, 2024. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Xianning
FEI numbers on the lines
3016784508
Refused lines
1
Lines with an Import Alert 66-80 API or powder code
1
Drugs named in the product codes
Tirzepatide
Refusal dates
Aug 5, 2024

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hubei JXBio Pharmaceutical Co., Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Aug 5, 2024China61PCZ74 TIRZEPATIDE (ANTI-DIABETIC)Sterile PowderUNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).XXX-0614347-6/1/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).1

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 4 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Hubei JXBio Pharmaceutical Co., Ltd” and “Hubei JXBio Pharmaceutical Co.,Ltd”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (3); BULK INGREDIENT (1).

76617-002Hubei JXBio Pharmaceutical Co., LtdNot givenliraglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMar 14, 2024None givenDec 31, 2026Unfinished drugs
76617-001Hubei JXBio Pharmaceutical Co.,LtdNot givensemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGNov 17, 2022None givenDec 31, 2026Unfinished drugs
76617-003Hubei JXBio Pharmaceutical Co.,LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTJan 9, 2025None givenDec 31, 2027Unfinished drugs
76617-020Hubei JXBio Pharmaceutical Co.,LtdNot givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGDec 5, 2022None givenDec 31, 2026Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

1 line from FDA files read Nov 15, 2026.